|
US7083786B2
(en)
|
1997-04-03 |
2006-08-01 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
EP2386316B1
(en)
|
2004-06-10 |
2018-02-28 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US7919094B2
(en)
*
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US8889127B2
(en)
|
2004-07-01 |
2014-11-18 |
Icahn School Of Medicine At Mount Sinai |
Targeted protein replacement for the treatment of lysosomal storage disorders
|
|
EP2357254A1
(en)
|
2005-02-14 |
2011-08-17 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
|
US20080269730A1
(en)
|
2005-04-14 |
2008-10-30 |
Dotson Robert S |
Ophthalmic Phototherapy Device and Associated Treatment Method
|
|
US20130079759A1
(en)
|
2005-04-14 |
2013-03-28 |
Robert S. Dotson |
Ophthalmic Phototherapy Device and Associated Treatment Method
|
|
US8524453B2
(en)
*
|
2006-02-10 |
2013-09-03 |
The Brigham And Woman's Hospital, Inc. |
Lectin complement pathway assays and related compositions and methods
|
|
KR101584468B1
(ko)
*
|
2006-03-08 |
2016-01-13 |
아케믹스 엘엘씨 |
안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
|
|
WO2007149567A2
(en)
|
2006-06-21 |
2007-12-27 |
Musc Foundation For Research Development |
Targeting complement factor h for treatment of diseases
|
|
EP2278987A4
(en)
*
|
2008-03-28 |
2012-08-22 |
Apellis Ag |
MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
|
|
WO2010039690A1
(en)
*
|
2008-09-30 |
2010-04-08 |
The Trustees Of The University Of Pennsylvania |
Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
|
|
LT2894165T
(lt)
|
2008-11-10 |
2023-03-10 |
Alexion Pharmaceuticals, Inc. |
Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
|
|
US9291622B2
(en)
|
2009-05-21 |
2016-03-22 |
Apellis Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
HUP0900319A2
(en)
*
|
2009-05-25 |
2011-01-28 |
Eotvos Lorand Tudomanyegyetem |
New peptides, method of producing therof and use thereof
|
|
JP5871798B2
(ja)
|
2009-07-02 |
2016-03-01 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
肝再生を刺激する方法
|
|
CN102781471B
(zh)
*
|
2009-10-16 |
2016-10-12 |
奥默罗斯公司 |
通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
|
|
MX2012005151A
(es)
|
2009-11-05 |
2012-08-23 |
Federico Ii University Of Naples |
Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
|
|
CN102844053B
(zh)
|
2009-11-25 |
2015-08-05 |
洛马林达大学医学中心 |
基于壳聚糖的止血织物
|
|
CA2791841C
(en)
|
2010-03-05 |
2023-01-03 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
|
EP2824111B1
(en)
|
2010-04-30 |
2017-03-22 |
Alexion Pharmaceuticals, Inc. |
Anti-C5A Antibodies and Methods for Using the Antibodies
|
|
WO2011143637A1
(en)
|
2010-05-14 |
2011-11-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Improved complement receptor 2 (cr2) targeting groups
|
|
US9815890B2
(en)
|
2010-06-22 |
2017-11-14 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the C3d fragment of complement component 3
|
|
HUP1000366A2
(en)
*
|
2010-07-13 |
2012-03-28 |
Mta Enzimologiai Intezet |
Novel proteins, their production process and use tereof
|
|
US9295713B2
(en)
*
|
2010-09-15 |
2016-03-29 |
Celldex Therapeutics, Inc. |
Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
|
|
AU2015271989B2
(en)
*
|
2011-04-08 |
2017-09-21 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
KR101870915B1
(ko)
*
|
2011-04-08 |
2018-06-25 |
유니버시티 오브 레스터 |
Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
|
|
AU2013201626B2
(en)
*
|
2011-04-08 |
2016-02-11 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
AU2013201779B2
(en)
*
|
2011-05-04 |
2016-01-07 |
Omeros Corporation |
Compositions for inhibiting MASP-2 dependent complement activation
|
|
EP2704743B1
(en)
|
2011-05-04 |
2020-03-11 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement acitivation
|
|
CN103796667A
(zh)
|
2011-06-22 |
2014-05-14 |
艾普莱斯制药公司 |
用补体抑制剂治疗慢性障碍的方法
|
|
AU2012278326A1
(en)
*
|
2011-06-28 |
2014-01-16 |
Kobenhavns Universitet |
Therapeutic targeting of Ficolin-3
|
|
US10350277B2
(en)
|
2011-09-07 |
2019-07-16 |
Icahn School Of Medicine At Mount Sinai |
Ceramidase and cell differentiation
|
|
WO2013106572A1
(en)
|
2012-01-11 |
2013-07-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
|
US20150297674A1
(en)
*
|
2012-03-12 |
2015-10-22 |
Loma Linda University Medical Center |
Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or disease
|
|
WO2013180834A2
(en)
*
|
2012-04-06 |
2013-12-05 |
Omeros Corporation |
Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
|
|
PL2854910T3
(pl)
|
2012-06-01 |
2020-07-27 |
Icahn School Of Medicine At Mount Sinai |
Poziomy ceramidu w leczeniu i zapobieganiu infekcjom
|
|
KR102339315B1
(ko)
|
2012-06-18 |
2021-12-15 |
오메로스 코포레이션 |
다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
|
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
|
CN104870475B
(zh)
|
2012-10-25 |
2019-11-08 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
|
DK2914291T3
(da)
|
2012-11-02 |
2022-05-16 |
Bioverativ Usa Inc |
Anti-komplement-c1s-antistoffer og anvendelser deraf
|
|
CA2905449C
(en)
|
2013-03-14 |
2024-09-10 |
Icahn School Of Medicine At Mount Sinai |
THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE
|
|
CA3216595A1
(en)
|
2013-03-14 |
2014-10-02 |
Kevin Fitzgerald |
Complement component c5 irna compositions and methods of use thereof
|
|
ES2964340T3
(es)
|
2013-03-15 |
2024-04-05 |
Omeros Corp |
Métodos para generar anticuerpos portadores de péptidos bioactivos y composiciones que comprenden los mismos
|
|
US20140363433A1
(en)
|
2013-03-15 |
2014-12-11 |
Omeros Corporation |
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
|
|
ES2768648T3
(es)
|
2013-03-29 |
2020-06-23 |
Alexion Pharma Inc |
Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
|
|
RU2549468C2
(ru)
*
|
2013-08-09 |
2015-04-27 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") |
Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека
|
|
SMT202000659T1
(it)
|
2013-10-17 |
2021-01-05 |
Omeros Corp |
Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2
|
|
SG10201804960RA
(en)
|
2013-12-12 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
US20150353623A1
(en)
*
|
2014-04-03 |
2015-12-10 |
Loma Linda University |
Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
|
|
US9259357B2
(en)
|
2014-04-16 |
2016-02-16 |
Loma Linda University |
Composition, preparation, and use of chitosan shards for biomedical applications
|
|
CN107072821B
(zh)
|
2014-09-09 |
2022-07-01 |
卢米希拉公司 |
用于损伤或患病组织的非侵入性治疗的多波长光疗装置、系统和方法
|
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
MX2017004742A
(es)
|
2014-10-20 |
2017-07-20 |
Nestec Sa |
Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
|
|
WO2016081314A1
(en)
|
2014-11-17 |
2016-05-26 |
Alexion Pharmaceuticals, Inc. |
Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
|
|
WO2016164358A1
(en)
|
2015-04-06 |
2016-10-13 |
True North Therapeutics, Inc. |
Humanized anti-c1s antibodies and methods of use thereof
|
|
EP4365291A3
(en)
|
2015-06-12 |
2024-08-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
CA3001661C
(en)
*
|
2015-10-14 |
2025-05-06 |
Massachusetts Eye And Ear Infirmary |
HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION
|
|
CN108472347B
(zh)
|
2015-11-09 |
2023-09-05 |
奥默罗斯公司 |
用于治疗与masp-2依赖性补体活化相关的病况的方法
|
|
US10736960B2
(en)
*
|
2016-01-05 |
2020-08-11 |
Omeros Corporation |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
WO2017173290A1
(en)
|
2016-03-31 |
2017-10-05 |
Omeros Corporation |
Methods for inhibiting angiogenesis in a subject in need thereof
|
|
KR20190005944A
(ko)
*
|
2016-05-09 |
2019-01-16 |
애넥슨, 인코포레이티드 |
척수성 근위축 치료용 조성물 및 방법
|
|
JP2019517473A
(ja)
|
2016-05-27 |
2019-06-24 |
アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
難治性全身型重症筋無力症の処置のための方法
|
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
CN109475626A
(zh)
*
|
2016-07-14 |
2019-03-15 |
儿童医院医疗中心 |
治疗纤维化的方法
|
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
|
HUE073475T2
(hu)
|
2016-10-12 |
2026-01-28 |
Bioverativ Usa Inc |
C1s elleni antitestek és alkalmazási eljárásaik
|
|
IL265981B2
(en)
*
|
2016-10-13 |
2025-05-01 |
Univ Leicester |
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
|
|
SI3658184T1
(sl)
|
2017-07-27 |
2024-01-31 |
Alexion Pharmaceuticals, Inc., |
Formulacije z visoko koncentracijo protiteles proti-C5
|
|
TWI818919B
(zh)
|
2017-08-15 |
2023-10-21 |
美商歐米諾斯公司 |
用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
|
|
CN107288615B
(zh)
*
|
2017-08-17 |
2023-05-16 |
西南石油大学 |
一种激光固相沉积仪器及其测试方法
|
|
CA3080187A1
(en)
|
2017-10-26 |
2019-05-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
|
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
CN112867706B
(zh)
|
2018-05-29 |
2024-11-15 |
奥默罗斯公司 |
Masp-2抑制剂和使用方法
|
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
|
US12404320B2
(en)
|
2018-05-31 |
2025-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
|
|
JP7577542B2
(ja)
|
2018-06-04 |
2024-11-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
|
|
WO2020006266A1
(en)
|
2018-06-28 |
2020-01-02 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-c5 antibodies
|
|
CN112996561A
(zh)
|
2018-10-30 |
2021-06-18 |
亚力兄制药公司 |
用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
|
|
CA3139209A1
(en)
|
2019-05-07 |
2020-11-12 |
Bayer Aktiengesellschaft |
Masp inhibitory compounds and uses thereof
|
|
KR102180733B1
(ko)
*
|
2019-07-12 |
2020-11-19 |
건국대학교 산학협력단 |
탈지우유를 유효성분으로 포함하는 줄기세포 분리용 조성물
|
|
RU2732765C1
(ru)
*
|
2019-07-25 |
2020-09-22 |
Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации |
Способ коррекции реперфузионно-ишемического повреждения при резекции почки по поводу локализованного рака в условиях тепловой ишемии
|
|
EP4054634A1
(en)
|
2019-11-08 |
2022-09-14 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-c5 antibody formulations
|
|
WO2021108447A1
(en)
*
|
2019-11-26 |
2021-06-03 |
Omeros Corporation |
Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
|
|
EP4069676A1
(en)
|
2019-12-04 |
2022-10-12 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
BR112022010881A2
(pt)
|
2019-12-04 |
2022-08-23 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
|
|
IL293550A
(en)
|
2019-12-04 |
2022-08-01 |
Omeros Corp |
2-masp inhibitor compounds, preparations containing them and their uses
|
|
JP7699389B2
(ja)
|
2019-12-04 |
2025-06-27 |
オメロス コーポレーション |
Ｍａｓｐ－２阻害剤および使用方法
|
|
WO2021163980A1
(zh)
*
|
2020-02-21 |
2021-08-26 |
中国人民解放军军事科学院军事医学研究院 |
靶向masp-2、n蛋白或其结合的物质预防和/或治疗冠状病毒感染
|
|
TWI834025B
(zh)
|
2020-03-06 |
2024-03-01 |
美商奥默羅斯公司 |
用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
|
|
MX2022013606A
(es)
|
2020-04-30 |
2023-01-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
|
|
CN111893090B
(zh)
*
|
2020-08-17 |
2023-10-27 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
一种动脉粥样硬化防治药物筛选细胞模型及其构建和应用
|
|
EP4240750A1
(en)
|
2020-11-04 |
2023-09-13 |
Bayer Aktiengesellschaft |
Masp inhibitory compounds and uses thereof
|
|
EP4011904A1
(en)
|
2020-12-14 |
2022-06-15 |
Bayer Aktiengesellschaft |
Masp inhibitory compounds and uses thereof
|
|
US11672761B2
(en)
|
2020-11-16 |
2023-06-13 |
Orcosa Inc. |
Rapidly infusing platform and compositions for therapeutic treatment in humans
|
|
WO2022103638A1
(en)
|
2020-11-16 |
2022-05-19 |
Orcosa Inc. |
Cannabinoids in the treatment of autism spectrum disorder
|
|
CN114634575B
(zh)
*
|
2020-12-16 |
2025-04-11 |
康诺亚生物医药科技（成都）有限公司 |
一种补体抑制剂的开发和应用
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
TW202305010A
(zh)
*
|
2021-04-25 |
2023-02-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
|
|
AU2022279806A1
(en)
*
|
2021-05-26 |
2023-11-30 |
Kao Corporation |
Agent for preventing or ameliorating pruritus
|
|
EP4353749A4
(en)
*
|
2021-06-08 |
2025-07-16 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
ANTI-MASP-2 ANTIBODY AND ITS USE
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
|
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子ｂ（ｃｆｂ）ｉｒｎａ組成物及其使用方法
|
|
WO2023108028A2
(en)
*
|
2021-12-10 |
2023-06-15 |
Omeros Corporation |
Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
|
|
JP2025541737A
(ja)
|
2022-11-30 |
2025-12-23 |
オメロス コーポレーション |
Ｍａｓｐ－２阻害物質としての縮合ピリミジン
|
|
EP4643878A2
(en)
*
|
2022-12-29 |
2025-11-05 |
Suzhou Transcenta Therapeutics Co., Ltd. |
Pharmaceutical preparation comprising therapeutic antibody and use thereof
|
|
US20250122225A1
(en)
|
2023-10-06 |
2025-04-17 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
WO2025092910A1
(zh)
*
|
2023-10-31 |
2025-05-08 |
石药集团中奇制药技术（石家庄）有限公司 |
一种抑制补体MASP2基因表达的dsRNA分子及其应用
|
|
WO2025199107A1
(en)
|
2024-03-19 |
2025-09-25 |
Alexion Pharmaceuticals, Inc. |
Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
|